Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-590 pembrolizumab plus cisplatin and fluorouracil in advanced or metastatic esophageal carcinoma
2017-000958-19Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in esophageal cancer and gastroesophageal junction adenocarcinoma comparing Pembrolizumab + cisplatin + fluorouracil with Placebo + cisplatin + fluorouracil (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Apr 2017; status: completed.
02
Drugs
03
Conditions
esophageal cancergastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2017-000958-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000958-19.